|
CO-ADMINISTRATION WITH AN ALUMINIUM AND MAGNESIUM CONTAINING ANTACID RESULTED IN A REDUCTION IN PLASMA CELECOXIB CONCENTRATION WITH A DECREASE OF 37% IN CMAX AND 10% IN AUC
|
CO-ADMINISTRATION WITH AN ALUMINIUM AND MAGNESIUM CONTAINING ANTACID RESULTED IN A REDUCTION IN PLASMA CELECOXIB CONCENTRATION WITH A DECREASE OF 37% IN CMAX AND 10% IN AUC
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|
REDUCED CLEARANCE OF CAFFEINE AND A PROLONGATION OF ITS SERUM HALF-LIFE
|
CO-ADMINISTRATION WITH CALCIUM-CONTAINING, MAY SUBSTANTIALLY INTERFERE WITH THE ORAL ABSORPTION OF QUINOLONES ; THESE PREPARATIONS MAY BE TAKEN SIX HRS. BEFORE OR 2 HRS. AFTER TAKING CIPROFLOXACIN
|
CO-ADMINISTRATION WITH CALCIUM-CONTAINING, MAY SUBSTANTIALLY INTERFERE WITH THE ORAL ABSORPTION OF QUINOLONES ; THESE PREPARATIONS MAY BE TAKEN SIX HRS. BEFORE OR 2 HRS. AFTER TAKING CIPROFLOXACIN
|
CO-ADMINISTRATION WITH CALCIUM-CONTAINING, MAY SUBSTANTIALLY INTERFERE WITH THE ORAL ABSORPTION OF QUINOLONES ; THESE PREPARATIONS MAY BE TAKEN SIX HRS. BEFORE OR 2 HRS. AFTER TAKING CIPROFLOXACIN
|
CO-ADMINISTRATION WITH CALCIUM-CONTAINING, MAY SUBSTANTIALLY INTERFERE WITH THE ORAL ABSORPTION OF QUINOLONES ; THESE PREPARATIONS MAY BE TAKEN SIX HRS. BEFORE OR 2 HRS. AFTER TAKING CIPROFLOXACIN
|
CO-ADMINISTRATION WITH CALCIUM-CONTAINING, MAY SUBSTANTIALLY INTERFERE WITH THE ORAL ABSORPTION OF QUINOLONES ; THESE PREPARATIONS MAY BE TAKEN SIX HRS. BEFORE OR 2 HRS. AFTER TAKING CIPROFLOXACIN
|
CO-ADMINISTRATION WITH CALCIUM-CONTAINING, MAY SUBSTANTIALLY INTERFERE WITH THE ORAL ABSORPTION OF QUINOLONES ; THESE PREPARATIONS MAY BE TAKEN SIX HRS. BEFORE OR 2 HRS. AFTER TAKING CIPROFLOXACIN
|
CO-ADMINISTRATION WITH CALCIUM-CONTAINING, MAY SUBSTANTIALLY INTERFERE WITH THE ORAL ABSORPTION OF QUINOLONES ; THESE PREPARATIONS MAY BE TAKEN SIX HRS. BEFORE OR 2 HRS. AFTER TAKING CIPROFLOXACIN
|
CO-ADMINISTRATION WITH CALCIUM-CONTAINING, MAY SUBSTANTIALLY INTERFERE WITH THE ORAL ABSORPTION OF QUINOLONES ; THESE PREPARATIONS MAY BE TAKEN SIX HRS. BEFORE OR 2 HRS. AFTER TAKING CIPROFLOXACIN
|
CO-ADMINISTRATION WITH CALCIUM-CONTAINING, MAY SUBSTANTIALLY INTERFERE WITH THE ORAL ABSORPTION OF QUINOLONES ; THESE PREPARATIONS MAY BE TAKEN SIX HRS. BEFORE OR 2 HRS. AFTER TAKING CIPROFLOXACIN
|
CO-ADMINISTRATION WITH CALCIUM-CONTAINING, MAY SUBSTANTIALLY INTERFERE WITH THE ORAL ABSORPTION OF QUINOLONES ; THESE PREPARATIONS MAY BE TAKEN SIX HRS. BEFORE OR 2 HRS. AFTER TAKING CIPROFLOXACIN
|
CO-ADMINISTRATION WITH CALCIUM-CONTAINING, MAY SUBSTANTIALLY INTERFERE WITH THE ORAL ABSORPTION OF QUINOLONES ; THESE PREPARATIONS MAY BE TAKEN SIX HRS. BEFORE OR 2 HRS. AFTER TAKING CIPROFLOXACIN
|
CO-ADMINISTRATION WITH CALCIUM-CONTAINING, MAY SUBSTANTIALLY INTERFERE WITH THE ORAL ABSORPTION OF QUINOLONES ; THESE PREPARATIONS MAY BE TAKEN SIX HRS. BEFORE OR 2 HRS. AFTER TAKING CIPROFLOXACIN
|
CO-ADMINISTRATION WITH CALCIUM-CONTAINING, MAY SUBSTANTIALLY INTERFERE WITH THE ORAL ABSORPTION OF QUINOLONES ; THESE PREPARATIONS MAY BE TAKEN SIX HRS. BEFORE OR 2 HRS. AFTER TAKING CIPROFLOXACIN
|
CO-ADMINISTRATION WITH CALCIUM-CONTAINING, MAY SUBSTANTIALLY INTERFERE WITH THE ORAL ABSORPTION OF QUINOLONES ; THESE PREPARATIONS MAY BE TAKEN SIX HRS. BEFORE OR 2 HRS. AFTER TAKING CIPROFLOXACIN
|
CO-ADMINISTRATION WITH CALCIUM-CONTAINING, MAY SUBSTANTIALLY INTERFERE WITH THE ORAL ABSORPTION OF QUINOLONES ; THESE PREPARATIONS MAY BE TAKEN SIX HRS. BEFORE OR 2 HRS. AFTER TAKING CIPROFLOXACIN
|
CO-ADMINISTRATION WITH CALCIUM-CONTAINING, MAY SUBSTANTIALLY INTERFERE WITH THE ORAL ABSORPTION OF QUINOLONES ; THESE PREPARATIONS MAY BE TAKEN SIX HRS. BEFORE OR 2 HRS. AFTER TAKING CIPROFLOXACIN
|
CO-ADMINISTRATION WITH CALCIUM-CONTAINING, MAY SUBSTANTIALLY INTERFERE WITH THE ORAL ABSORPTION OF QUINOLONES ; THESE PREPARATIONS MAY BE TAKEN SIX HRS. BEFORE OR 2 HRS. AFTER TAKING CIPROFLOXACIN
|
CO-ADMINISTRATION WITH CALCIUM-CONTAINING, MAY SUBSTANTIALLY INTERFERE WITH THE ORAL ABSORPTION OF QUINOLONES ; THESE PREPARATIONS MAY BE TAKEN SIX HRS. BEFORE OR 2 HRS. AFTER TAKING CIPROFLOXACIN
|
ADDITIVE ACTIVITY OFTEN RESULTS WHEN QUINOLONES ARE COMBINED WITH AMINOGLYCOSIDES
|
ADDITIVE ACTIVITY OFTEN RESULTS WHEN QUINOLONES ARE COMBINED WITH AMINOGLYCOSIDES
|
ADDITIVE ACTIVITY OFTEN RESULTS WHEN QUINOLONES ARE COMBINED WITH AMINOGLYCOSIDES
|
ADDITIVE ACTIVITY OFTEN RESULTS WHEN QUINOLONES ARE COMBINED WITH AMINOGLYCOSIDES
|
ADDITIVE ACTIVITY OFTEN RESULTS WHEN QUINOLONES ARE COMBINED WITH AMINOGLYCOSIDES
|
ADDITIVE ACTIVITY OFTEN RESULTS WHEN QUINOLONES ARE COMBINED WITH AMINOGLYCOSIDES
|
ADDITIVE ACTIVITY OFTEN RESULTS WHEN QUINOLONES ARE COMBINED WITH AMINOGLYCOSIDES
|
ADDITIVE ACTIVITY OFTEN RESULTS WHEN QUINOLONES ARE COMBINED WITH AMINOGLYCOSIDES
|
ADDITIVE ACTIVITY OFTEN RESULTS WHEN QUINOLONES ARE COMBINED WITH AMINOGLYCOSIDES
|
ADDITIVE ACTIVITY OFTEN RESULTS WHEN QUINOLONES ARE COMBINED WITH AMINOGLYCOSIDES
|
AVOID CONCOMITANT PRESCRIPTION WITH MEDICATIONS KNOWN TO PROLONG QTC INTERVAL LIKE ERYTHROMYCIN, TERFENADINE, ASTEMIZOLE, CISAPRIDE, PENTAMIDINE, TRICYCLIC ANTIDEPRESSANTS & SOME ANTIPSYCHOTICS INCLUDING PHENOTHIAZINES
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
ACHILLES AND OTHER TENDON REPTURE HAS BEEN REPORTED WITH QUINOLONES; ALTHOUGH NOT REPORTED IN CLINICAL TRIAL WITH MOXIFLOXACIN,POST MARKET SURVEILLANCE REPORTS THAT THE RISK MAY BE INCREASED IN PATIENTS ON CONCOMITANT CORTICOSTEROIDS
|
ACHILLES AND OTHER TENDON REPTURE HAS BEEN REPORTED WITH QUINOLONES; ALTHOUGH NOT REPORTED IN CLINICAL TRIAL WITH MOXIFLOXACIN,POST MARKET SURVEILLANCE REPORTS THAT THE RISK MAY BE INCREASED IN PATIENTS ON CONCOMITANT CORTICOSTEROIDS
|
ACHILLES AND OTHER TENDON REPTURE HAS BEEN REPORTED WITH QUINOLONES; ALTHOUGH NOT REPORTED IN CLINICAL TRIAL WITH MOXIFLOXACIN,POST MARKET SURVEILLANCE REPORTS THAT THE RISK MAY BE INCREASED IN PATIENTS ON CONCOMITANT CORTICOSTEROIDS
|
ACHILLES AND OTHER TENDON REPTURE HAS BEEN REPORTED WITH QUINOLONES; ALTHOUGH NOT REPORTED IN CLINICAL TRIAL WITH MOXIFLOXACIN,POST MARKET SURVEILLANCE REPORTS THAT THE RISK MAY BE INCREASED IN PATIENTS ON CONCOMITANT CORTICOSTEROIDS
|
ACHILLES AND OTHER TENDON REPTURE HAS BEEN REPORTED WITH QUINOLONES; ALTHOUGH NOT REPORTED IN CLINICAL TRIAL WITH MOXIFLOXACIN,POST MARKET SURVEILLANCE REPORTS THAT THE RISK MAY BE INCREASED IN PATIENTS ON CONCOMITANT CORTICOSTEROIDS
|
ACHILLES AND OTHER TENDON REPTURE HAS BEEN REPORTED WITH QUINOLONES; ALTHOUGH NOT REPORTED IN CLINICAL TRIAL WITH MOXIFLOXACIN,POST MARKET SURVEILLANCE REPORTS THAT THE RISK MAY BE INCREASED IN PATIENTS ON CONCOMITANT CORTICOSTEROIDS
|
ACHILLES AND OTHER TENDON REPTURE HAS BEEN REPORTED WITH QUINOLONES; ALTHOUGH NOT REPORTED IN CLINICAL TRIAL WITH MOXIFLOXACIN,POST MARKET SURVEILLANCE REPORTS THAT THE RISK MAY BE INCREASED IN PATIENTS ON CONCOMITANT CORTICOSTEROIDS
|
ACHILLES AND OTHER TENDON REPTURE HAS BEEN REPORTED WITH QUINOLONES; ALTHOUGH NOT REPORTED IN CLINICAL TRIAL WITH MOXIFLOXACIN,POST MARKET SURVEILLANCE REPORTS THAT THE RISK MAY BE INCREASED IN PATIENTS ON CONCOMITANT CORTICOSTEROIDS
|
PROLONGATION OF QT INTERVAL MAY BE SERIOUS COMPLICATION
|
PROLONGATION OF QT INTERVAL MAY BE SERIOUS COMPLICATION
|
PROLONGATION OF QT INTERVAL MAY BE SERIOUS COMPLICATION
|
CONCURRENT ADMINISTRATION OF THESE ANTACIDS MAY SUBSTANTIALLY INTERFERE WITH THE ORAL ABSORPTION OF CIPROFLOXACIN ; ANTACIDS SHOULD BE GIVEN 2 HRS. AFTER OR 6 HRS. BEFORE COPROFLOXACIN DOSING WITHOUT A SIGNIFICANT DECREASE IN BIOAVAILABILITY
|
CONCURRENT ADMINISTRATION OF THESE ANTACIDS MAY SUBSTANTIALLY INTERFERE WITH THE ORAL ABSORPTION OF CIPROFLOXACIN ; ANTACIDS SHOULD BE GIVEN 2 HRS. AFTER OR 6 HRS. BEFORE COPROFLOXACIN DOSING WITHOUT A SIGNIFICANT DECREASE IN BIOAVAILABILITY
|
CONCURRENT ADMINISTRATION OF THESE ANTACIDS MAY SUBSTANTIALLY INTERFERE WITH THE ORAL ABSORPTION OF CIPROFLOXACIN ; ANTACIDS SHOULD BE GIVEN 2 HRS. AFTER OR 6 HRS. BEFORE COPROFLOXACIN DOSING WITHOUT A SIGNIFICANT DECREASE IN BIOAVAILABILITY
|
CONCURRENT ADMINISTRATION OF THESE ANTACIDS MAY SUBSTANTIALLY INTERFERE WITH THE ORAL ABSORPTION OF CIPROFLOXACIN ; ANTACIDS SHOULD BE GIVEN 2 HRS. AFTER OR 6 HRS. BEFORE COPROFLOXACIN DOSING WITHOUT A SIGNIFICANT DECREASE IN BIOAVAILABILITY
|
CONCURRENT ADMINISTRATION OF THESE ANTACIDS MAY SUBSTANTIALLY INTERFERE WITH THE ORAL ABSORPTION OF CIPROFLOXACIN ; ANTACIDS SHOULD BE GIVEN 2 HRS. AFTER OR 6 HRS. BEFORE COPROFLOXACIN DOSING WITHOUT A SIGNIFICANT DECREASE IN BIOAVAILABILITY
|
CONCURRENT ADMINISTRATION OF THESE ANTACIDS MAY SUBSTANTIALLY INTERFERE WITH THE ORAL ABSORPTION OF CIPROFLOXACIN ; ANTACIDS SHOULD BE GIVEN 2 HRS. AFTER OR 6 HRS. BEFORE COPROFLOXACIN DOSING WITHOUT A SIGNIFICANT DECREASE IN BIOAVAILABILITY
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ERYTHROMYCIN, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ERYTHROMYCIN, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ERYTHROMYCIN, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ERYTHROMYCIN, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ERYTHROMYCIN, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF QUINOLONES WITH ZINC-CONTAINING PRODUCTS MAY SUBSTANTIALLY INTERFERE WITH THE ABSORPTION OF QUINOLONES; IT SHOULD BE TAKEN 4 HOURS BEFORE OR 8 HRS. AFTER INGESTION OF ZINC-CONTAINING PRODUCTS
|
CO-ADMINISTRATION OF QUINOLONES WITH ZINC-CONTAINING PRODUCTS MAY SUBSTANTIALLY INTERFERE WITH THE ABSORPTION OF QUINOLONES; IT SHOULD BE TAKEN 4 HOURS BEFORE OR 8 HRS. AFTER INGESTION OF ZINC-CONTAINING PRODUCTS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
TRANSIENT ELEVATIONS IN SERUM CREATININE
|
DIDANOSINE SHOULD BE TAKEN 2 HRS AFTER OR 6 HRS BEFORE QUINOLONES LIKE CIPROFLOXACIN
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
QUINOLONES MAY INCREASE THE EFFECT OF THEOPHYLLINE
|
GATIFLOXACIN MAY HAVE THE POTENTIAL TO PROLONG THE QT INTERVAL ; CO-ADMINISTRATION WITH DRUGS KNOWN TO PROLONG QT INTERVAL SHOULD BE AVOIDED
|
GATIFLOXACIN MAY HAVE THE POTENTIAL TO PROLONG THE QT INTERVAL ; CO-ADMINISTRATION WITH DRUGS KNOWN TO PROLONG QT INTERVAL SHOULD BE AVOIDED
|
GATIFLOXACIN MAY HAVE THE POTENTIAL TO PROLONG THE QT INTERVAL ; CO-ADMINISTRATION WITH DRUGS KNOWN TO PROLONG QT INTERVAL SHOULD BE AVOIDED
|